drugset
drugset / Trial / NCT03969888

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

NCT03969888 ↗

Phase 2 Completed 78 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.

Timeline

Start
2019-12-11
Primary completion
2022-06-09
Completion
2022-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Galicaftor Small molecule 10 mg Oral
Subject Galicaftor Small molecule 30 mg Oral
Subject Galicaftor Small molecule 100 mg Oral
Subject Galicaftor Small molecule 200 mg Oral
Subject Galicaftor Small molecule 300 mg Oral
Subject Navocaftor Small molecule 50 mg Oral
Subject Navocaftor Small molecule 150 mg Oral

Indications

cystic fibrosis